Michiel de Bruin

High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs

Sven Rottenberg, Janneke E. Jaspers, Ariena Kersbergen et al. · Proceedings of the National Academy of Sciences · 2008 · 943 citations · Full text

Breast Oncology, Pathology, Cancer Biology +17

Selective Inhibition of BRCA2-Deficient Mammary Tumor Cell Growth by AZD2281 and Cisplatin

Bastiaan Evers, Rinske Drost, Eva Schut et al. · Clinical Cancer Research · 2008 · 331 citations · Full text

Reversal of resistance by GF120918 in cell lines expressing the ABC half-transporter, MXR

Michiel de Bruin, Keisuke Miyake, Thomas Litman et al. · Cancer Letters · 1999 · 295 citations

Signal Transduction, Molecular Physiology, Cell Signaling +10

An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients

Marieke A. Vollebergh, Esther H. Lips, Petra M. Nederlof et al. · Annals of Oncology · 2010 · 208 citations · Full text

Fibroblast Growth Factor Receptor 1–Transformed Mammary Epithelial Cells Are Dependent on RSK Activity for Growth and Survival

Wa Xian, Leontios Pappas, Darshan Pandya et al. · Cancer Research · 2009 · 72 citations · Full text

Breast Oncology, Pathology, Cell Proliferation +19